Actualités Gpc Biotech AG ADS (MM) - GPCB | Actions NASDAQ

GPC Biotech Reports That Marketing Authorization Application for Satraplatin is to Be Withdrawn

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) reported that the Company has been informed by its partner for...

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1...

GPC Biotech to Present at Two Upcoming Conferences: 7th Annual Needham Biotechnology & Medical Technology Conference in New York

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that the Company will give a corporate presentation...

Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemothe

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced the presentation of the overall survival results...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Gpc Biotech AG ADS (MM) (GPCB)

Outils de qualité professionnelle, pour des investisseurs individuels.

GPCB Actualités

GPC Biotech Reports That Marketing Authorization Application for Satraplatin is to Be Withdrawn

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

GPC Biotech to Present at Two Upcoming Conferences: 7th Annual Needham Biotechnology & Medical Technology Conference in New York

Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemothe

New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting

GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting

GPC Biotech Reports Financial Results for First Quarter 2008

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Amended Statement of Ownership (SC 13G/A)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Gpc Biotech AG ADS (MM) (GPCB) Actualités

Gpc Biotech AG ADS (MM) (GPCB)

Outils de qualité professionnelle, pour des investisseurs individuels.

GPCB Actualités

GPC Biotech Reports That Marketing Authorization Application for Satraplatin is to Be Withdrawn

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

GPC Biotech to Present at Two Upcoming Conferences: 7th Annual Needham Biotechnology & Medical Technology Conference in New York

Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemothe

New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting

GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting

GPC Biotech Reports Financial Results for First Quarter 2008

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Amended Statement of Ownership (SC 13G/A)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

Gpc Biotech Ag - Report of Foreign Issuer (6-K)

GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application